Indian woman cancer-free after experimental drug trial in UK

A woman of Indian descent who had just a few months to live a few years ago celebrates on Monday after doctors said she had no signs of breast cancer following a clinical trial at a hospital British.

Jasmin David, 51, from Fallowfield in Manchester, is now looking forward to celebrating her 25th wedding anniversary in September after a successful National Health Service (NHS) trial.

David’s two-year trial at the Christie NHS Foundation Trust’s National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) involved an investigational drug combined with Atezolizumab, an immunotherapy drug given intravenously which she continues to have every three weeks.

I was 15 months later after my first cancer treatment and had almost forgotten about it, but the cancer came back, David recalls.

When I was offered the trial, I didn’t know if it would work for me, but I thought at least I could do something to help others and use my body for the next generation. At first I had many horrible side effects including headaches and temperature spikes so I was in the hospital by Christmas and pretty bad. Then, luckily, I started to respond well to the treatment, she said.

The previously fit and healthy mother of two adult children, worked as a clinical manager at a care home for the elderly.

She found out she had an aggressive triple-negative form of breast cancer in November 2017 when she found a lump above her nipple.

She underwent six months of chemotherapy and a mastectomy in April 2018, followed by 15 cycles of radiation therapy which rid her body of cancer.

Then, in October 2019, the cancer returned and scans showed multiple lesions throughout her body, meaning she had a poor prognosis.

The cancer had spread to the lungs, lymph nodes and chest bone and she received the devastating news that she had less than a year to live. Two months later, and with no other options, David was offered the opportunity to be part of research by participating in a Phase I clinical trial.

I celebrated my 50th birthday in February 2020 while still in treatment and unsure of what the future held. Two and a half years ago I thought it was the end and now I feel like I’ve been reborn, David said.

There is a change in my life after returning from India to see my family in April and I have decided to take early retirement and live my life in gratitude to God and medical science. My family was very supportive of this decision. I will be celebrating my 25th wedding anniversary in September. I have so much to look forward to, she said.

My Christian faith helped me a lot on this journey and the prayers and support of my family and friends gave me the strength to face the challenge, she added. In June 2021, scans showed no measurable cancer cells in her body and she was deemed cancer-free. She will remain on treatment until December 2023 but continues to show no signs of the disease.

We are really happy that Jasmin had such a good result. At The Christie, we are continually testing new drugs and therapies to see if they can benefit more people, said Professor Fiona Thistlethwaite, Medical Oncologist and Clinical Director of Manchester CRF at The Christie.

(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

Back To Top